FDA Approvals in Oncology: July-September 2026
During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options...
Category: FDA Approvals
During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options...
During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment...
In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
In the second quarter of 2025, the FDA issued 13 new oncology approvals, including options for rare cancers, head...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are...
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...